At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 30, 2026 at 16:16 ET
Disc Medicine amended its existing loan agreement with Hercules Capital, drawing $30M from Tranche 1-B and restructuring the remaining $50M Tranche 1-C into two $25M tranches. The amendment also extends draw periods for Tranches 2 and 3 to late 2027/2028 and defers the minimum cash covenant test to July 2028, providing extended financial flexibility for a pre-revenue biotech.
- Disc Medicine drew $30M under Tranche 1-B of the Hercules Capital loan agreement.
- The existing $50M Tranche 1-C was split into a $25M tranche available through March 31, 2027, and a $25M Tranche 1-D available through April 30, 2027.
- Draw periods for Tranche 2 and Tranche 3 advances were extended to December 15, 2027 and June 30, 2028, respectively.
- Minimum cash covenant initial testing date was deferred to July 1, 2028.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access